GoTHAM : A Phase Ib/II Study of Combination Avelumab With Peptide Receptor Radionuclide Therapy or Conventional Fractionated Radiotherapy in Patients With Metastatic Merkel Cell Carcinoma

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Multiple<Br/>Treatment TypesTypeMultiple
Treatment Types

One/TwoPhase One/Two

18+Age Over 18

Skin<br/>CancersCancer LocationSkin
Cancers

Multiple treatment types,Radiotherapy,Systemic therapy,Treatment | SkinMerkel cell

Trial Overview Read MoreRead more

This phase I/II trial is evaluating the safety and effectiveness of an immunotherapy combined with a type of radionuclide therapy or external beam radiation therapy in patients with Merkel Cell Carcinoma that has spread to other parts of the body.
 

This trial is treating patients with Merkel Cell Carcinoma.

This is a systemic therapy and radiotherapy trial.

You may be able to join this trial if:

  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase Ib/II Study of Combination Avelumab With Peptide Receptor Radionuclide Therapy or Conventional Fractionated Radiotherapy in Patients With Metastatic Merkel Cell Carcinoma

Other Non-Commercial Sponsor

Melanoma and Skin Cancer Trials Limited

Summary

All eligible patients will receive intravenous Avelumab at 10mg/kg every two weeks for 24 months or until unacceptable toxicity or evidence of disease progression. Depending on the group to which they are randomised, enrolled patients will either receive 177-Lu-DOTATATE treatment or external beam radiotherapy on 2 occasions, 8-10 weeks apart.

Recruiting Hospitals Read MoreRead more

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Enquiries Line Coordinator
clinicaltrials.enquiries@petermac.org
03 8559 7456 (9am-2pm, Mon-Fri)

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next